Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.77
CRME's Cash to Debt is ranked lower than
82% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CRME: 0.77 )
Ranked among companies with meaningful Cash to Debt only.
CRME' s 10-Year Cash to Debt Range
Min: 0.77  Med: 84.28 Max: No Debt
Current: 0.77
Equity to Asset 0.33
CRME's Equity to Asset is ranked lower than
83% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CRME: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
CRME' s 10-Year Equity to Asset Range
Min: -0.01  Med: 0.79 Max: 0.99
Current: 0.33
-0.01
0.99
F-Score: 3
Z-Score: -7.55
M-Score: -2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -59.36
CRME's Operating margin (%) is ranked higher than
51% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CRME: -59.36 )
Ranked among companies with meaningful Operating margin (%) only.
CRME' s 10-Year Operating margin (%) Range
Min: -12543.75  Med: -1214.24 Max: 55.51
Current: -59.36
-12543.75
55.51
Net-margin (%) -68.33
CRME's Net-margin (%) is ranked higher than
50% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CRME: -68.33 )
Ranked among companies with meaningful Net-margin (%) only.
CRME' s 10-Year Net-margin (%) Range
Min: -12075  Med: -1319.72 Max: 105.81
Current: -68.33
-12075
105.81
ROE (%) -84.03
CRME's ROE (%) is ranked lower than
77% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. CRME: -84.03 )
Ranked among companies with meaningful ROE (%) only.
CRME' s 10-Year ROE (%) Range
Min: -127.25  Med: -60.79 Max: 93.76
Current: -84.03
-127.25
93.76
ROA (%) -39.18
CRME's ROA (%) is ranked lower than
62% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. CRME: -39.18 )
Ranked among companies with meaningful ROA (%) only.
CRME' s 10-Year ROA (%) Range
Min: -101.59  Med: -41.34 Max: 46.4
Current: -39.18
-101.59
46.4
ROC (Joel Greenblatt) (%) -321.64
CRME's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. CRME: -321.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRME' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4604.34  Med: -1253.95 Max: 1546.19
Current: -321.64
-4604.34
1546.19
Revenue Growth (3Y)(%) 154.00
CRME's Revenue Growth (3Y)(%) is ranked higher than
98% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CRME: 154.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRME' s 10-Year Revenue Growth (3Y)(%) Range
Min: -75.8  Med: 43.00 Max: 205.2
Current: 154
-75.8
205.2
EBITDA Growth (3Y)(%) -20.60
CRME's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CRME: -20.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRME' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -47.5  Med: 2.70 Max: 27
Current: -20.6
-47.5
27
EPS Growth (3Y)(%) -17.90
CRME's EPS Growth (3Y)(%) is ranked lower than
63% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CRME: -17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRME' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.7  Med: -0.30 Max: 24.2
Current: -17.9
-48.7
24.2
» CRME's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CRME Guru Trades in Q2 2014

Jim Simons 143,298 sh (-35.05%)
» More
Q3 2014

CRME Guru Trades in Q3 2014

Jim Simons 84,113 sh (-41.30%)
» More
Q4 2014

CRME Guru Trades in Q4 2014

Jim Simons 77,113 sh (-8.32%)
» More
Q1 2015

CRME Guru Trades in Q1 2015

Jim Simons 97,113 sh (+25.94%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 312.50
CRME's Forward P/E is ranked lower than
94% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. CRME: 312.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 11.18
CRME's P/B is ranked lower than
80% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CRME: 11.18 )
Ranked among companies with meaningful P/B only.
CRME' s 10-Year P/B Range
Min: 1.02  Med: 6.91 Max: 29.65
Current: 11.18
1.02
29.65
P/S 6.14
CRME's P/S is ranked higher than
68% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. CRME: 6.14 )
Ranked among companies with meaningful P/S only.
CRME' s 10-Year P/S Range
Min: 3.24  Med: 23.05 Max: 305.91
Current: 6.14
3.24
305.91
Current Ratio 1.80
CRME's Current Ratio is ranked lower than
76% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. CRME: 1.80 )
Ranked among companies with meaningful Current Ratio only.
CRME' s 10-Year Current Ratio Range
Min: 1.14  Med: 7.79 Max: 97.75
Current: 1.8
1.14
97.75
Quick Ratio 1.47
CRME's Quick Ratio is ranked lower than
76% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. CRME: 1.47 )
Ranked among companies with meaningful Quick Ratio only.
CRME' s 10-Year Quick Ratio Range
Min: 1.14  Med: 7.79 Max: 97.75
Current: 1.47
1.14
97.75
Days Inventory 219.37
CRME's Days Inventory is ranked lower than
75% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. CRME: 219.37 )
Ranked among companies with meaningful Days Inventory only.
CRME' s 10-Year Days Inventory Range
Min: 207.9  Med: 747.09 Max: 1286.27
Current: 219.37
207.9
1286.27
Days Sales Outstanding 95.93
CRME's Days Sales Outstanding is ranked lower than
71% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. CRME: 95.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRME' s 10-Year Days Sales Outstanding Range
Min: 4.04  Med: 187.47 Max: 2418.13
Current: 95.93
4.04
2418.13

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.26
CRME's Price/Median PS Value is ranked higher than
93% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. CRME: 0.26 )
Ranked among companies with meaningful Price/Median PS Value only.
CRME' s 10-Year Price/Median PS Value Range
Min: 0.18  Med: 1.78 Max: 78.26
Current: 0.26
0.18
78.26
Earnings Yield (Greenblatt) (%) -9.50
CRME's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CRME: -9.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRME' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 8.10 Max: 1418014.8
Current: -9.5
1
1418014.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:COM.Canada, CKO1.Germany,
Cardiome Pharma Corp was incorporated on December 12, 1986. The Company is a specialty pharmaceutical company engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It currently has two marketed, in-hospital, cardiology products, BRINAVESS, for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adultsand and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in Acute Coronary Syndrome patients. Both of its products are commercially available in numerous markets outside of the United States. BRINAVESS was approved in September 2010 and has been launched in the European Union, Iceland and Norway.
» More Articles for CRME

Headlines

Articles On GuruFocus.com
Cardiome Pharma Corp. Increases Bought Deal Financing to US$20.0 Million Jul 29 2015 
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

More From Other Websites
CARDIOME PHARMA CORP Financials Jul 31 2015
Cardiome Pharma Corp. Increases Bought Deal Financing to US$20.0 Million Jul 29 2015
Cardiome Pharma Corp. Increases Bought Deal Financing to US$20.0 Million Jul 29 2015
Cardiome Announces Approximately US$15.0 Million Bought Deal Financing Jul 28 2015
Cardiome To Hold Second Quarter 2015 Results Conference Call on August 5 Jul 28 2015
Cardiome Pharma Corp. Announces Approximately US$15.0 Million Bought Deal Financing Jul 28 2015
Cardiome to Hold Second Quarter 2015 Financial Results Conference Call on August 5 Jul 28 2015
Cardiome to Hold Second Quarter 2015 Financial Results Conference Call on August 5 Jul 28 2015
Cardiome Partner Eddingpharm To Initiate Brinavess Phase I Study In China Jul 27 2015
Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China Jul 24 2015
Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China Jul 24 2015
Dermira (DERM) Looks Good: Stock Adds 8.1% in Session - Tale of the Tape Jul 23 2015
Cardiome Submits Supplemental New Drug Submission (SNDS) For Aggrastat To Health Canada Jul 22 2015
Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada Jul 22 2015
Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada Jul 22 2015
Aldeyra Therapeutics (ALDX) Worth a Look: Stock Up 7.8% - Tale of the Tape Jul 21 2015
PTC Therapeutics (PTCT) Jumps: Stock Surges 14.4% - Tale of the Tape Jul 16 2015
New Strong Buy Stocks for July 6th - Tale of the Tape Jul 06 2015
Steadymed And Cardiome Enter Into A License Agreement For The Commercialization Rights To TREVYENT®... Jun 29 2015
SteadyMed and Cardiome Enter into a License Agreement for the Commercialization Rights to Trevyent®... Jun 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK